Reckitt is in a ‘unique position to address the baby formula crisis’


Reckitt is in a ‘unique position to address the baby formula crisis’

Ad disclosure

Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >


Wajeeh Khan

Jun 3, 2022

Reckitt SVP discusses the company’s role in addressing baby formula shortage.

The British firm has greatly expanded its U.S. market share since February.

Shares of the consumer goods company are down more than 2.0% year-to-date.

Reckitt Benckiser Group plc (LON: RKT) is in a “unique position” to address the ongoing baby formula crisis, says Senior Vice President Robert Cleveland.

Cleveland’s remarks on CNBC’s ‘Closing Bell’

The British multinational is waiting for approval from the FDA to bring the product it produces at its Singapore and Mexican facilities to the United States. On CNBC’s “Closing Bell”, Cleveland said:

Are you looking for fast-news, hot-tips and market analysis?

Sign-up for the Invezz newsletter, today.

We’ve submitted paperwork to the FDA. We’re ready to start production as soon as we get the approval. We’ll put the product on the shelves quickly because its under the Enfamil brand where we already have distribution and consumers know the brand.

Also on Thursday, President Biden ordered his administration to mobilize all available tools to ramp up supply of baby formula that meets safety standards.

Reckitt has greatly increased its market share

Since Abbott factory shutdown, Reckitt Benckiser has increased its share in the U.S. market for concentrated formula from 34% to 54%. Speaking with CNBC’s Sara Eisen, the Senior Vice President said:

We’re the 2nd largest manufacturer in the U.S. and so, we were the most able to step up, increase production, and run our plants 24/7. We’ve delivered 30% more to the market than we were a year ago. Absence of a major competitor has put us in that position.

Abbott recalled formula products and closed its Sturgis plant in February, after reports of at least two infants getting sick with Cronobacter sakazakii infections.

Invest in crypto, stocks, ETFs & more in minutes with our preferred broker,


75.26% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you can afford to take the high risk of losing your money.

Visit site


Health & pharmaceuticals



North America

Stocks & Shares




Generated by Feedzy